Enspryng (satralizumab-mwge)

In NMOSD, Enspryng promotes B-cells’ anti-inflammatory profile

Enspryng (satralizumab-mwge) promotes an anti-inflammatory profile in plasmablasts, the immune cells that produce large amounts of the self-reactive antibodies that drive most cases of neuromyelitis optica spectrum disorder (NMOSD). That’s according to a study analyzing immune cells from NMOSD patients before and after treatment with Enspryng, as well…

AAN 2023: Enspryng still safe, effective after 4.5 years in trials

Up to 4.6 years of treatment with Enspryng (satralizumab) continues to safely reduce relapse rates and prevent disability progression for people with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). That’s according to pooled data from the Phase 3 SAkuraSky (NCT02028884) and…

Choosing Between a Medication That’s Proven Effective and a Better Quality of Life

Since 2012, I have been using Rituxan (rituximab) to treat my neuromyelitis optica. I had no major complaints about it until 2018. My neurologist back then referred me to an immunologist, who recommended I start immunoglobulin replacement therapy (IVIG) to increase the levels of immunoglobulins that had been…

Recently Approved NMO Medications Are a Light on the Horizon

When I was diagnosed with neuromyelitis optica (NMO) in 2012, the U.S. Food and Drug Administration (FDA) hadn’t yet approved any medications specifically to treat this disease. However, doctors could select various therapies to help patients prevent or deal with attacks. When NMO patients had an attack, doctors treated…